Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Alx Oncology Holdings Inc (ALXO)

Alx Oncology Holdings Inc (ALXO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate GlobeNewswire - Mon Apr 7, 7:00AM CDT

ALXO : 0.5500 (-1.79%)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge Newswire.ca - Sat Mar 8, 6:33AM CST

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.5610 (-1.23%)
EXEL : 36.19 (+0.11%)
ONC.TO : 0.77 (-1.28%)
ALXO : 0.5500 (-1.79%)
CRDF : 2.85 (+1.42%)
VSTM : 5.74 (+15.73%)
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update GlobeNewswire - Thu Mar 6, 3:01PM CST

ALXO : 0.5500 (-1.79%)
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event GlobeNewswire - Wed Mar 5, 7:00AM CST

ALXO : 0.5500 (-1.79%)
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 GlobeNewswire - Thu Feb 27, 7:00AM CST

ALXO : 0.5500 (-1.79%)
ALX Oncology to Host Virtual R&D Day on March 5, 2025 GlobeNewswire - Tue Feb 18, 7:00AM CST

ALXO : 0.5500 (-1.79%)
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer GlobeNewswire - Thu Jan 23, 7:00AM CST

ALXO : 0.5500 (-1.79%)
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules GlobeNewswire - Wed Jan 22, 3:01PM CST

ALXO : 0.5500 (-1.79%)
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors GlobeNewswire - Wed Jan 22, 7:00AM CST

ALXO : 0.5500 (-1.79%)
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI GlobeNewswire - Tue Jan 21, 4:00PM CST

ALXO : 0.5500 (-1.79%)

Barchart Exclusives

This Dividend Stock Yields Nearly 8% and Trades at Depressed Valuations: Time to Buy? Barchart - Thu Apr 17, 6:30PM CDT
Amid the continued decline in Pfizer stock, its dividend yield has risen to almost 8%. While the stock might not be a screaming buy, it now seems to have limited downside. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot